These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 8599909)
41. Knowledge and use of papanicolaou test among HIV-positive women. Serraino D; Pavia C; Navarra A; Piselli P; Pisani G; Scuderi M; Secchia SB; Capobianchi M; Ippolito G; Int J Cancer; 2005 Jul; 115(6):1009-10. PubMed ID: 15751031 [No Abstract] [Full Text] [Related]
42. Pap smears. Do them right and every year--forever! Gall SA Postgrad Med; 1989 May; 85(6):235-9. PubMed ID: 2710727 [TBL] [Abstract][Full Text] [Related]
44. A randomized trial of three methods of obtaining Papanicolaou smears. Fokke HE; Salvatore CM; Schipper ME; Bleker OP Eur J Obstet Gynecol Reprod Biol; 1993 Feb; 48(2):103-6. PubMed ID: 8491328 [TBL] [Abstract][Full Text] [Related]
45. Atypical squamous cells of undetermined significance: a comparative review of original and automated rescreen diagnosis of cervicovaginal smears with long term follow-up. Stastny JF; Remmers RE; London WB; Pedigo MA; Cahill LA; Ryan M; Frable WJ Cancer; 1997 Dec; 81(6):348-53. PubMed ID: 9438460 [TBL] [Abstract][Full Text] [Related]
46. Papanicolaou smears and risk of cervical neoplasia. La Vecchia C; Franceschi S; Decarli A Lancet; 1984 Dec; 2(8415):1335. PubMed ID: 6150339 [No Abstract] [Full Text] [Related]
47. Pap smears, prevention, primary care, and the guarantee of good health. Curran WJ Am J Public Health; 1981 Jun; 71(6):646-7. PubMed ID: 7235107 [No Abstract] [Full Text] [Related]
48. Women getting regular care may prefer Pap tests for cancer screening. Perspect Sex Reprod Health; 2015 Jun; 47(2):110. PubMed ID: 26095737 [No Abstract] [Full Text] [Related]
49. Cost-effectiveness of methods to enhance sensitivity of Papanicolaou testing. Sedlacek TV JAMA; 1999 Oct; 282(15):1419-20. PubMed ID: 10535424 [No Abstract] [Full Text] [Related]
50. Cost-effectiveness of methods to enhance sensitivity of Papanicolaou testing. Leidy NK; Brown R; Luce B; Sheets E JAMA; 1999 Oct; 282(15):1419; author reply 1420. PubMed ID: 10535423 [No Abstract] [Full Text] [Related]
51. Breast and cervical cancer screening for women with intellectual disabilities. Swaine JG; Parish SL; Luken K Health Soc Work; 2013 Aug; 38(3):183-6. PubMed ID: 24437024 [No Abstract] [Full Text] [Related]
52. Papanicolaou smear adequacy: the effect of the sampling sequence. Noel ML; Kazal LA; Glenday MC J Am Board Fam Pract; 1993; 6(2):103-7. PubMed ID: 8452061 [TBL] [Abstract][Full Text] [Related]
53. A more accurate measure of the false-negative rate of Papanicolaou smear screening is obtained by determining the false-negative rate of the rescreening process. Renshaw AA; DiNisco SA; Minter LJ; Cibas ES Cancer; 1997 Oct; 81(5):272-6. PubMed ID: 9349513 [TBL] [Abstract][Full Text] [Related]
54. Problems and progress with Pap smear screening reviewed. Volkers N J Natl Cancer Inst; 1992 Nov; 84(22):1694-5. PubMed ID: 1433354 [No Abstract] [Full Text] [Related]
55. [Pap smear screening for the control of cervical cancer in Minas Gerais State, Brazil, 2002]. Feitosa TM; Almeida RT Cad Saude Publica; 2007 Apr; 23(4):907-17. PubMed ID: 17435888 [TBL] [Abstract][Full Text] [Related]
56. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Goldie SJ; Weinstein MC; Kuntz KM; Freedberg KA Ann Intern Med; 1999 Jan; 130(2):97-107. PubMed ID: 10068381 [TBL] [Abstract][Full Text] [Related]
57. The Papanicolaou smear and the cervigram. A preliminary report. Gundersen JH; Schauberger CW; Rowe NR J Reprod Med; 1988 Jan; 33(1):46-8. PubMed ID: 3351806 [TBL] [Abstract][Full Text] [Related]